Utility of Circulating Tumor DNA (ctDNA) Assessments to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib in Combination with the ATR Inhibitor Camonsertib in the Phase I MYTHIC trial
Time: 8:30 am
day: Day One
Details:
- Examining the role of ctDNA assessments in the early clinical development of the lunresertib and camonsertib combination, with a focus on confirmation rates of enrollment alterations
- Using ctDNA data to support dose and schedule selection for the combination therapy in the Phase I MYTHIC trial
- Correlating early ctDNA kinetics with clinical outcomes to evaluate the effectiveness of the treatment approach
